Inqovi Maintenance Therapy in Myeloid Neoplasms
Key claim: Oral decitabine/cedazuridine (Inqovi) is being evaluated as post-transplant maintenance therapy to reduce relapse risk in MDS and CMML patients following allogeneic stem cell transplant.
Abstract
This research is being done to see if the drug Inqov is effective in reducing the chance of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) relapsing after standard of care stem cell transplant.
- This research study involves the study drug Inqovi, which is a combination of the drugs decitabine and cedazuridine.
Why this matters
Post-transplant maintenance is an underdeveloped lever in MPN/MDS transplant decision-making, where relapse drives most late failures. A prospective trial of oral decitabine/cedazuridine extends a familiar hypomethylating agent into the maintenance setting with the convenience of oral dosing, and positive results could reshape post-HCT management algorithms — including potential extrapolation to MPN-AP/BP patients who currently lack a standard maintenance option.